FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199161608> ?p ?o ?g. }

• W3199161608 endingPage "101" @default.
• W3199161608 startingPage "100" @default.
• W3199161608 abstract "Background: Chimeric antigen receptor T cells (CAR-T) cells targeting CD19, demonstrate highly effective anti-tumor response in Diffuse Large B Cell Lymphoma (DLBCL). However, can result in significant side effects such as prolong neutropenia and infections. The incidence of infections in the setting of real world data hasn't been completely identified. Aims: To perform a comprehensive analysis of infection rate and profile in the first month after CAR-T cells in a cohort of infirm patients treated with commercially available CAR-T cells. Methods: This is a retrospective, single center study conducted in the Bone marrow transplant unit, Tel Aviv, analyzing the infection rate in consecutive patients with DLBCL who were treated with commercially available axicabtagene ciloleucel or tisagenlecleucel. Following a local protocol, all patients were treated with prophylaxis with ciprofloxacin and fluconazole when neutrophil counts decreased below 0.5∗103/μl. Acyclovir was administered at conditioning initiation. Microbiology and clinical documented infections (MDI and CDI, respectively) were defined according to the ECIL guidelines. Following white blood cell recovery, patients carried out weekly full blood count, and monthly CMV and HHV-6. A logistic regression was performed for the association between baseline characteristics and documented infections. Results: From June 2019 to December 2020, we included 60 consecutive patients with DLBCL treated with axicabtagene ciloleucel (n=16, 27%) or tisagenlecleucel (n=44, 73%). The median age was 69.3 (range, 19.8-85.2) years and ECOG-Performance status(PS) was 2-3 in most patients (58%). Broad spectrum antibiotics was administered to patients experiencing neutropenic fever (n=53, 88%). Overall infections were noted in 27/60 patients (45%).Bacterial infections were seen in 16 patients (27%) and included CDI in 7 (Pneumonia, n=5;periodontal infection, n=1 and cellulitis, n=1) and MDI in 9 patients (Gram negative rod bacteremia (GNR), n= 5;Gram positive cocci(GPC) bacteremia, n= 3;Both GNR and GPC, n=1). Viral infection was described in 14 patients (23%). The most common viral infection was CMV reactivation (n=10, 17%) leading to initiation of anti-CMV treatment in 6 among these patients. None had CMV disease. HHV-6 was positive in 3 patients (5%) with one of these patients presenting with acute encephalitis. Other viral infections reported were RSV (n=2)COVID-19 (n=1). No fungal infection was documented. Incidence of documented infections was higher in patients with CRS/ICANS compared with patients without [23/44 (52%) vs 4/16 (25%), p=0.005]. While CRP levels predicted documented infections (p= 0.041), ferritin blood levels did not (p=0.130). In univariate analysis, ICANS (OR= 4.5, p = 0.018) was associated with higher incidence of bacterial infection while there was a trend for lower incidence of bacterial infections in patients with chemo-sensitive disease to bridging therapy (OR= 0.375, p= 0.074)(Table 1). Age or ECOG-PS were not associated with increased risk of bacterial infection. Patients with documented infection had an increase in hospitalization days compared to those without documented infection (26.44 vs 21.7 days, p= 0.085). Summary/Conclusion: Infections were common in the first month following CAR-T cell administration, however were not increased in elderly patients or those presenting with poorer PS. Patients refractory to bridging therapy and ICANS should be monitored cautiously for the occurrence of infections. CMV monitoring should also be considered." @default.
• W3199161608 created "2021-09-27" @default.
• W3199161608 creator A5008022437 @default.
• W3199161608 creator A5020859772 @default.
• W3199161608 creator A5033960326 @default.
• W3199161608 creator A5035063918 @default.
• W3199161608 creator A5035942514 @default.
• W3199161608 creator A5044054666 @default.
• W3199161608 creator A5047815444 @default.
• W3199161608 creator A5053411706 @default.
• W3199161608 creator A5053631638 @default.
• W3199161608 creator A5076333833 @default.
• W3199161608 creator A5079688295 @default.
• W3199161608 creator A5088097249 @default.
• W3199161608 date "2021-01-01" @default.
• W3199161608 modified "2023-09-26" @default.
• W3199161608 title "Early infections following commercial anti-CD19 CAR-T Cells infirm population - A single center retrospective study" @default.
• W3199161608 hasPublicationYear "2021" @default.
• W3199161608 type Work @default.
• W3199161608 sameAs 3199161608 @default.
• W3199161608 citedByCount "2" @default.
• W3199161608 countsByYear W31991616082021 @default.
• W3199161608 crossrefType "journal-article" @default.
• W3199161608 hasAuthorship W3199161608A5008022437 @default.
• W3199161608 hasAuthorship W3199161608A5020859772 @default.
• W3199161608 hasAuthorship W3199161608A5033960326 @default.
• W3199161608 hasAuthorship W3199161608A5035063918 @default.
• W3199161608 hasAuthorship W3199161608A5035942514 @default.
• W3199161608 hasAuthorship W3199161608A5044054666 @default.
• W3199161608 hasAuthorship W3199161608A5047815444 @default.
• W3199161608 hasAuthorship W3199161608A5053411706 @default.
• W3199161608 hasAuthorship W3199161608A5053631638 @default.
• W3199161608 hasAuthorship W3199161608A5076333833 @default.
• W3199161608 hasAuthorship W3199161608A5079688295 @default.
• W3199161608 hasAuthorship W3199161608A5088097249 @default.
• W3199161608 hasBestOaLocation W31991616081 @default.
• W3199161608 hasConcept C126322002 @default.
• W3199161608 hasConcept C167135981 @default.
• W3199161608 hasConcept C203014093 @default.
• W3199161608 hasConcept C2776694085 @default.
• W3199161608 hasConcept C2777063308 @default.
• W3199161608 hasConcept C2778559949 @default.
• W3199161608 hasConcept C2779338263 @default.
• W3199161608 hasConcept C2780073493 @default.
• W3199161608 hasConcept C2908647359 @default.
• W3199161608 hasConcept C71924100 @default.
• W3199161608 hasConcept C90924648 @default.
• W3199161608 hasConcept C99454951 @default.
• W3199161608 hasConceptScore W3199161608C126322002 @default.
• W3199161608 hasConceptScore W3199161608C167135981 @default.
• W3199161608 hasConceptScore W3199161608C203014093 @default.
• W3199161608 hasConceptScore W3199161608C2776694085 @default.
• W3199161608 hasConceptScore W3199161608C2777063308 @default.
• W3199161608 hasConceptScore W3199161608C2778559949 @default.
• W3199161608 hasConceptScore W3199161608C2779338263 @default.
• W3199161608 hasConceptScore W3199161608C2780073493 @default.
• W3199161608 hasConceptScore W3199161608C2908647359 @default.
• W3199161608 hasConceptScore W3199161608C71924100 @default.
• W3199161608 hasConceptScore W3199161608C90924648 @default.
• W3199161608 hasConceptScore W3199161608C99454951 @default.
• W3199161608 hasLocation W31991616081 @default.
• W3199161608 hasLocation W31991616082 @default.
• W3199161608 hasLocation W31991616083 @default.
• W3199161608 hasOpenAccess W3199161608 @default.
• W3199161608 hasPrimaryLocation W31991616081 @default.
• W3199161608 hasRelatedWork W2013076223 @default.
• W3199161608 hasRelatedWork W2044946374 @default.
• W3199161608 hasRelatedWork W2091803058 @default.
• W3199161608 hasRelatedWork W2094936280 @default.
• W3199161608 hasRelatedWork W2180137691 @default.
• W3199161608 hasRelatedWork W2327452818 @default.
• W3199161608 hasRelatedWork W2360768073 @default.
• W3199161608 hasRelatedWork W2391052960 @default.
• W3199161608 hasRelatedWork W2530940708 @default.
• W3199161608 hasRelatedWork W2554273028 @default.
• W3199161608 hasRelatedWork W2555408005 @default.
• W3199161608 hasRelatedWork W2765852438 @default.
• W3199161608 hasRelatedWork W2806027620 @default.
• W3199161608 hasRelatedWork W2913769617 @default.
• W3199161608 hasRelatedWork W3030500968 @default.
• W3199161608 hasRelatedWork W3164485832 @default.
• W3199161608 hasRelatedWork W3166289863 @default.
• W3199161608 hasRelatedWork W3179689693 @default.
• W3199161608 hasRelatedWork W978172877 @default.
• W3199161608 hasRelatedWork W3210525272 @default.
• W3199161608 hasVolume "5" @default.
• W3199161608 isParatext "false" @default.
• W3199161608 isRetracted "false" @default.
• W3199161608 magId "3199161608" @default.
• W3199161608 workType "article" @default.